Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Cancer Res. 2011 Mar 15;71(6):2183–2192. doi: 10.1158/0008-5472.CAN-10-3626

Figure 1. CARMA3 deficiency affects cell cycle and cancer cell growth.

Figure 1

(A) MDA-468 cells with stably expressing CARMA3 shRNA (sh47 and sh48) or negative control (GFP) were seeded in 96-well plates. Cell proliferation was examined at 24, 48, and 72 hours, respectively, by the MTT assay. The absorbance at 570 nm at different time points was determined. The experiment was repeated for three times, and the result from one of these experiments is presented. (B) MTT assay was similarly performed to examine the growth rate of A431 cells with CARMA3 shRNA (sh47) or mock control. (C) Above MDA cells were grown in DMEM complete media for overnight. The cells were harvested, fixed, and subjected to Propidium Iodide (PI) staining for cell cycle analysis by FACS. Data from different cell cycle phase was presented as percentage of cells (**P<0.01, *p>0.05). (D) Real-time PCR were performed to detect the expression level of Cyclin D1 using total RNA were prepared from MDA468 cells (WT), or MDA468 cells transduced with control shRNA for GFP (Mock) or CARMA3 shRNA (sh47 and sh48). The expression level of GAPDH was used as internal controls.